DescriptionAlendronate Sodium is a potent nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase in osteoclasts, reducing bone resorption and increasing bone density. Widely used for research in osteoporosis modeling, Paget’s disease, and bone metabolism dynamics. The Kaijian formulation provides a consistent 10?mg dose per tablet, enabling controlled in vitro and in vivo studies on skeletal tissues.Manufactured by Hainan Kaijian Pharmaceutical Co., Ltd., this product is approved under China’s NMPA registration number H20064818, drug code 86905788000016, barcode 6935642308068. Ideal for preclinical research settings. ?? Not intended for therapeutic use. Contents hide 1 Alendronate Sodium Tablets Product Specifications 2 Alendronate Sodium Tablets Mechanism & Research Applications 3 Alendronate Sodium Tablets Side Effects (Research Observations) 4 Safety & Handling 5 Core Keywords 6 Research Use Disclaimer Alendronate Sodium Tablets Product SpecificationsParameterDetailsProduct NameAlendronate Sodium Tablets (Kaijian)Generic NameAlendronate SodiumCAS Number121268?17?5Molecular FormulaC?H??NNaO?P?·3H?OMolecular Weight325.12?g/molDosage FormFilm-coated oral tabletStrength10?mg per tabletQuantity10 tablets per boxApproval NumberH20064818 (China NMPA)Product Code86905788000016ManufacturerHainan Kaijian Pharmaceutical Co., Ltd.Barcode6935642308068Storage ConditionsStore sealed at 20–25?°C, away from moistureIntended UseLaboratory research onlyAlendronate Sodium Tablets Mechanism & Research ApplicationsAlendronate Sodium works by binding to bone hydroxyapatite and inhibiting osteoclast-mediated bone resorption via farnesyl pyrophosphate synthase inhibition. It’s widely used for:Osteoporosis and bone density modelingInvestigating Paget’s disease in preclinical studiesBone turnover and remodeling assaysMuscle–bone interaction modelsComparative studies with other bisphosphonatesAlendronate Sodium Tablets Side Effects (Research Observations)Research and clinical data report potential effects such as:Gastric and esophageal irritation or ulcerationReduced calcium absorption and transient hypocalcemiaMusculoskeletal discomfort or bone/joint painRare adverse effects in long-term dosing: osteonecrosis of the jaw, atypical femur fracturesUse proper monitoring and welfare protocols in in vivo models.Safety & HandlingUse Restriction: Laboratory research only; not for clinical, therapeutic, or veterinary useHandling: Use lab-grade PPE—gloves, lab coat, and eye protectionStorage: Keep sealed at 20–25?°C, away from moistureDisposal: Dispose unused tablets following institutional hazardous waste guidelinesCore KeywordsAlendronate sodium tablets, Kaijian alendronate, 10?mg bisphosphonate research, bone resorption inhibitor, osteoporosis model compound, lab-grade alendronate, NMPA H20064818 alendronate, Hainan Kaijian alendronate, wholesale bone research tabletsResearch Use DisclaimerThis product is exclusively for laboratory research use and not approved for therapeutic, diagnostic, clinical, or veterinary applications. Misuse may pose safety or regulatory risks. Always use within authorized institutional biosafety protocols.
